Login Register Cart 0
Generic placeholder image

Current Vascular Pharmacology

Editor-in-Chief

ISSN (Print): 1570-1611
ISSN (Online): 1875-6212

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Cardiovascular Disease in Juvenile Idiopathic Arthritis

Author(s): Elisavet Arsenaki, Panagiotis Georgakopoulos, Panagiota Mitropoulou, Evangelia Koutli, Konstantinos Thomas, Marietta Charakida and Georgios Georgiopoulos*

Volume 18, Issue 6, 2020

Page: [580 - 591] Pages: 12

DOI: 10.2174/1570161118666200408121307

Price: $65

Abstract

Juvenile idiopathic arthritis (JIA), is a term used to describe a group of inflammatory disorders beginning before the age of 16 years. Although for the majority of children remission is achieved early, those with systemic or polyarticular form of the disease may present persistent symptoms in adulthood. Considering that there is overlap in the pathogenesis of JIA with adult rheumatic diseases, concerns have been raised as to whether JIA patients could be at increased cardiovascular (CV) risk in the long-term. In this review, we summarize evidence for CV involvement in JIA and present data on CV risk factors and surrogate markers of arterial disease. We also provide information on beneficial and harmful CV effects of anti-inflammatory medications in the context of JIA and suggest strategies for CV screening. Overall, patients with systemic forms of JIA demonstrate an adverse lipid profile and early arterial changes relevant to accelerated arterial disease progression. Although there is paucity of data on CV outcomes, we recommend a holistic approach in the management of JIA patients, which includes CV risk factor monitoring and lifestyle modification as well as use, when necessary, of antiinflammatory therapies with documented CV safety.

Keywords: Juvenile idiopathic arthritis, cardiovascular, surrogate markers, outcomes, disease, inflammatory.

« Previous Next »
Graphical Abstract

[1]
Prakken B, Albani S, Martini A. Juvenile idiopathic arthritis. Lancet 2011; 377(9783): 2138-49.
[http://dx.doi.org/10.1016/S0140-6736(11)60244-4 ] [PMID: 21684384]
[2]
Petty RE, Southwood TR, Manners P, et al. International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004; 31(2): 390-2.
[PMID: 14760812]
[3]
Martini A, Ravelli A, Avcin T, et al. Toward new classification criteria for juvenile idiopathic arthritis: first steps, pediatric rheumatology international trials organization international consensus. J Rheumatol 2019; 46(2): 190-7.
[http://dx.doi.org/10.3899/jrheum.180168 ] [PMID: 30275259]
[4]
Coulson EJ, Ng W-F, Goff I, Foster HE. Cardiovascular risk in juvenile idiopathic arthritis. Rheumatology (Oxford) 2013; 52(7): 1163-71.
[http://dx.doi.org/10.1093/rheumatology/ket106 ] [PMID: 23502074]
[5]
Skeoch S, Bruce IN. Atherosclerosis in rheumatoid arthritis: is it all about inflammation? Nat Rev Rheumatol 2015; 11(7): 390-400.
[http://dx.doi.org/10.1038/nrrheum.2015.40 ] [PMID: 25825281]
[6]
Berthold E, Månsson B, Kahn R. Outcome in juvenile idiopathic arthritis: a population-based study from Sweden. Arthritis Res Ther 2019; 21(1): 218.
[http://dx.doi.org/10.1186/s13075-019-1994-8 ] [PMID: 31661011]
[7]
Nordal E, Zak M, Aalto K, et al. Ongoing disease activity and changing categories in a long-term nordic cohort study of juvenile idiopathic arthritis. Arthritis Rheum 2011; 63(9): 2809-18.
[http://dx.doi.org/10.1002/art.30426 ] [PMID: 21560116]
[8]
Selvaag AM, Aulie HA, Lilleby V, Flatø B. Disease progression into adulthood and predictors of long-term active disease in juvenile idiopathic arthritis. Ann Rheum Dis 2016; 75(1): 190-5.
[http://dx.doi.org/10.1136/annrheumdis-2014-206034 ] [PMID: 25362042]
[9]
Oguz D, Ocal B, Ertan U, Narin H, Karademir S, Senocak F. Left ventricular diastolic functions in juvenile rheumatoid arthritis. Pediatr Cardiol 2000; 21(4): 374-7.
[http://dx.doi.org/10.1007/s002460010084 ] [PMID: 10865017]
[10]
Alkady EAM, Helmy HAR, Mohamed-Hussein AAR. Assessment of cardiac and pulmonary function in children with juvenile idiopathic arthritis. Rheumatol Int 2012; 32(1): 39-46.
[http://dx.doi.org/10.1007/s00296-010-1548-5 ] [PMID: 20658239]
[11]
Koca B, Bakari S, Kasapçopur O, et al. P wave dispersion in juvenile idiopathic arthritis patients with diastolic dysfunction. Iran J Pediatr 2012; 22(4): 512-8.
[PMID: 23430383]
[12]
Bohr A-H, Fuhlbrigge RC, Pedersen FK, de Ferranti SD, Müller K. Premature subclinical atherosclerosis in children and young adults with juvenile idiopathic arthritis. A review considering preventive measures. Pediatr Rheumatol Online J 2016; 14(1): 3.
[http://dx.doi.org/10.1186/s12969-015-0061-5 ] [PMID: 26738563]
[13]
Mani P, Uno K, Duong M, et al. HDL function and subclinical atherosclerosis in juvenile idiopathic arthritis. Cardiovasc Diagn Ther 2016; 6(1): 34-43.
[PMID: 26885490]
[14]
Turoňová L, Kubejová K, Vorčáková K, Ďurdík P, Péčová T, Martinásková K. Endothelial Dysfunction in Children with Juvenile Psoriatic Arthritis. Acta Med (Hradec Kral czech republic) 2018; 61(3): 79-85.
[http://dx.doi.org/10.14712/18059694.2018.122] [PMID: 30543511]
[15]
Bharti BB, Kumar S, Kapoor A, Agarwal A, Mishra R, Sinha N. Assessment of left ventricular systolic and diastolic function in juvenile rheumatoid arthritis. J Postgrad Med 2004; 50(4): 262-5.
[PMID: 15623966]
[16]
Breda L, Di Marzio D, Giannini C, et al. Relationship between inflammatory markers, oxidant-antioxidant status and intima-media thickness in prepubertal children with juvenile idiopathic arthritis. Clin Res Cardiol 2013; 102(1): 63-71.
[http://dx.doi.org/10.1007/s00392-012-0496-3 ] [PMID: 22885951]
[17]
Aulie HA, Selvaag AM, Günther A, et al. Arterial haemodynamics and coronary artery calcification in adult patients with juvenile idiopathic arthritis. Ann Rheum Dis 2015; 74(8): 1515-21.
[http://dx.doi.org/10.1136/annrheumdis-2013-204804 ] [PMID: 24695010]
[18]
Aulie HA, Estensen M-E, Selvaag AM, Lilleby V, Flatø B, Aakhus S. Arterial properties in adults with long-lasting active juvenile idiopathic arthritis compared to healthy controls. Pediatr Rheumatol Online J 2018; 16(1): 85.
[http://dx.doi.org/10.1186/s12969-018-0302-5 ] [PMID: 30594204]
[19]
Ahmad H, Othman G, Farrag S, et al. Subclinical heart failure in juvenile idiopathic arthritis: a consequence of chronic inflammation and subclinical atherosclerosis. Egypt Rheumatol Rehabil 2016; 43: 78.
[http://dx.doi.org/10.4103/1110-161X.181881]
[20]
Urbina EM, Williams RV, Alpert BS, et al. Noninvasive assessment of subclinical atherosclerosis in children and adolescents: recommendations for standard assessment for clinical research: a scientific statement from the American Heart Association. Hypertension 2009; 54(5): 919-50.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.109.192639 ] [PMID: 19729599]
[21]
Ferrari R. The role of TNF in cardiovascular disease. Pharmacol Res 1999; 40(2): 97-105.
[http://dx.doi.org/10.1006/phrs.1998.0463 ] [PMID: 10433867]
[22]
Lianza AC, Aikawa NE, Moraes JCB, et al. Long-term evaluation of cardiac function in juvenile idiopathic arthritis under anti-TNF therapy. Clin Exp Rheumatol 2014; 32(5): 754-9.
[PMID: 25152021]
[23]
Abul MH, Erguven M, Ozben B, Ayhan YI. The forgotten chamber: right-ventricular functions in juvenile idiopathic arthritis. Pediatr Cardiol 2012; 33(5): 739-43.
[http://dx.doi.org/10.1007/s00246-012-0203-1 ] [PMID: 22349671]
[24]
Gupta M, Rao PS. Cardiac function in juvenile rheumatoid arthritis. J Postgrad Med 2004; 50: 266-7.
[25]
Yancey CL, Doughty RA, Cohlan BA, Athreya BH. Pericarditis and cardiac tamponade in juvenile rheumatoid arthritis. Pediatrics 1981; 68(3): 369-73.
[PMID: 7279462]
[26]
Goldenberg J, Pessoa AP, Roizenblatt S, et al. Cardiac tamponade in juvenile chronic arthritis: report of two cases and review of publications. Ann Rheum Dis 1990; 49(7): 549-53.
[http://dx.doi.org/10.1136/ard.49.7.549 ] [PMID: 2088321]
[27]
Abston ED, Barin JG, Cihakova D, et al. IL-33 independently induces eosinophilic pericarditis and cardiac dilation: ST2 improves cardiac function. Circ Heart Fail 2012; 5(3): 366-75.
[http://dx.doi.org/10.1161/CIRCHEARTFAILURE.111.963769 ] [PMID: 22454393]
[28]
Ashley EA, Niebauer J. Infective endocarditis. In: Cardiology Explained. London Remedica 2004.
[29]
Sarzi-Puttini P, Atzeni F, Doria A, Iaccarino L, Turiel M. Tumor necrosis factor-alpha, biologic agents and cardiovascular risk. Lupus 2005; 14(9): 780-4.
[http://dx.doi.org/10.1191/0961203305lu2220oa ] [PMID: 16218487]
[30]
Anderson JH, Anderson KR, Aulie HA, et al. Juvenile idiopathic arthritis and future risk for cardiovascular disease: a multicenter study. Scand J Rheumatol 2016; 45(4): 299-303.
[http://dx.doi.org/10.3109/03009742.2015.1126345 ] [PMID: 26854592]
[31]
Raab A, Sengler C, Niewerth M, et al. Comorbidity profiles among adult patients with juvenile idiopathic arthritis: results of a biologic register. Clin Exp Rheumatol 2013; 31(5): 796-802.
[PMID: 23557722]
[32]
Libby P. Inflammation in atherosclerosis. Nature 2002; 420(6917): 868-74.
[http://dx.doi.org/10.1038/nature01323 ] [PMID: 12490960]
[33]
Mohan S, Barsalou J, Bradley TJ, et al. Endothelial progenitor cell phenotype and function are impaired in childhood-onset systemic lupus erythematosus. Arthritis Rheumatol 2015; 67(8): 2257-62.
[http://dx.doi.org/10.1002/art.39149 ] [PMID: 25891295]
[34]
Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: testing and clinical relevance. Circulation 2007; 115(10): 1285-95.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.106.652859 ] [PMID: 17353456]
[35]
Hill JM, Zalos G, Halcox JPJ, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003; 348(7): 593-600.
[http://dx.doi.org/10.1056/NEJMoa022287 ] [PMID: 12584367]
[36]
Werner N, Kosiol S, Schiegl T, et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 2005; 353(10): 999-1007.
[http://dx.doi.org/10.1056/NEJMoa043814 ] [PMID: 16148285]
[37]
Lee PSS, Poh KK. Endothelial progenitor cells in cardiovascular diseases. World J Stem Cells 2014; 6(3): 355-66.
[http://dx.doi.org/10.4252/wjsc.v6.i3.355 ] [PMID: 25126384]
[38]
Shantsila E, Watson T, Lip GYH. Endothelial progenitor cells in cardiovascular disorders. J Am Coll Cardiol 2007; 49(7): 741-52.
[http://dx.doi.org/10.1016/j.jacc.2006.09.050 ] [PMID: 17306702]
[39]
Werner N, Wassmann S, Ahlers P, et al. Endothelial progenitor cells correlate with endothelial function in patients with coronary artery disease. Basic Res Cardiol 2007; 102(6): 565-71.
[http://dx.doi.org/10.1007/s00395-007-0680-1 ] [PMID: 17932708]
[40]
Liao KP, Solomon DH. Traditional cardiovascular risk factors, inflammation and cardiovascular risk in rheumatoid arthritis. Rheumatology (Oxford) 2013; 52(1): 45-52.
[http://dx.doi.org/10.1093/rheumatology/kes243 ] [PMID: 22986289]
[41]
Tselepis AD, Elisaf M, Besis S, Karabina SA, Chapman MJ, Siamopoulou A. Association of the inflammatory state in active juvenile rheumatoid arthritis with hypo-high-density lipoproteinemia and reduced lipoprotein-associated platelet-activating factor acetylhydrolase activity. Arthritis Rheum 1999; 42(2): 373-83.
[http://dx.doi.org/10.1002/1529-0131(199902)42:2<373:AID-ANR21>3.0.CO;2-3 ] [PMID: 10025933]
[42]
Ilowite NT, Samuel P, Beseler L, Jacobson MS. Dyslipoproteinemia in juvenile rheumatoid arthritis. J Pediatr 1989; 114(5): 823-6.
[http://dx.doi.org/10.1016/S0022-3476(89)80148-9 ] [PMID: 2715897]
[43]
Marangoni RG, Hayata AL, Borba EF, Azevedo PM, Bonfá E, Schainberg CG. Decreased high-density lipoprotein cholesterol levels in polyarticular juvenile idiopathic arthritis. Clinics (São Paulo) 2011; 66(9): 1549-52.
[http://dx.doi.org/10.1590/S1807-59322011000900007 ] [PMID: 22179157]
[44]
Gonçalves M, D’Almeida V, Guerra-Shinohara EM, Galdieri LC, Len CA, Hilário MO. Homocysteine and lipid profile in children with Juvenile Idiopathic Arthritis. Pediatr Rheumatol Online J 2007; 5: 2.
[http://dx.doi.org/10.1186/1546-0096-5-2 ] [PMID: 17550630]
[45]
Hsia J, Margolis KL, Eaton CB, et al. Prehypertension and cardiovascular disease risk in the Women’s Health Initiative. Circulation 2007; 115(7): 855-60.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.106.656850 ] [PMID: 17309936]
[46]
Huang Y, Wang S, Cai X, et al. Prehypertension and incidence of cardiovascular disease: a meta-analysis. BMC Med 2013; 11: 177.
[http://dx.doi.org/10.1186/1741-7015-11-177 ] [PMID: 23915102]
[47]
Georgiopoulos G, Oikonomou D, Pateras K, et al. A Bayesian meta-analysis on early tobacco exposure and vascular health: From childhood to early adulthood. Eur J Prev Cardiol 2019.2047487319883557
[http://dx.doi.org/10.1177/2047487319883557 ] [PMID: 31747795]
[48]
Nash AA, Britto MT, Lovell DJ, Passo MH, Rosenthal SL. Substance use among adolescents with juvenile rheumatoid arthritis. Arthritis Care Res 1998; 11(5): 391-6.
[http://dx.doi.org/10.1002/art.1790110510 ] [PMID: 9830883]
[49]
Surís J-C, Michaud P-A, Akre C, Sawyer SM. Health risk behaviors in adolescents with chronic conditions. Pediatrics 2008; 122(5): e1113-8.
[http://dx.doi.org/10.1542/peds.2008-1479 ] [PMID: 18977960]
[50]
Takken T, van Brussel M, Engelbert RHH, Van der Net J, Kuis W, Helders PJ. Exercise therapy in juvenile idiopathic arthritis. Cochrane Database Syst Rev 2008; 16(2): CD005954.
[PMID: 18425929]
[51]
van Pelt PA, Takken T, van Brussel M, de Witte I, Kruize AA, Wulffraat NM. Aerobic capacity and disease activity in children, adolescents and young adults with juvenile idiopathic arthritis (JIA). Pediatr Rheumatol Online J 2012; 10(1): 27.
[http://dx.doi.org/10.1186/1546-0096-10-27 ] [PMID: 22925405]
[52]
Pelajo CF, Lopez-Benitez JM, Miller LC. Obesity and disease activity in juvenile idiopathic arthritis. Pediatr Rheumatol Online J 2012; 10(1): 3.
[http://dx.doi.org/10.1186/1546-0096-10-3 ] [PMID: 22240096]
[53]
Amine B, Ibn Yacoub Y, Rostom S, Hajjaj-Hassouni N. Prevalence of overweight among Moroccan children and adolescents with juvenile idiopathic arthritis. Joint Bone Spine 2011; 78(6): 584-6.
[http://dx.doi.org/10.1016/j.jbspin.2011.02.001 ] [PMID: 21441059]
[54]
Głowińska-Olszewska B, Bossowski A, Dobreńko E, et al. Subclinical cardiovascular system changes in obese patients with juvenile idiopathic arthritis. Mediators Inflamm 2013; 2013: 436702.
[http://dx.doi.org/10.1155/2013/436702 ] [PMID: 23554546]
[55]
Evensen K, Aulie HA, Rønning OM, Flatø B, Russell D. Carotid atherosclerosis in adult patients with persistently active juvenile idiopathic arthritis compared with healthy controls. J Rheumatol 2016; 43(4): 810-5.
[http://dx.doi.org/10.3899/jrheum.150499 ] [PMID: 26879363]
[56]
Sozeri B, Atikan BY, Ozdemir K, Mir S. Assessment of vascular function in systemic onset juvenile idiopathic arthritis. Clin Rheumatol 2016; 35(7): 1699-703.
[http://dx.doi.org/10.1007/s10067-016-3254-5 ] [PMID: 27075461]
[57]
Pietrewicz E, Urban M. Early atherosclerosis changes in children with juvenile idiopathic arthritis. Pol Merkuriusz Lek 2007; 22(129): 211-4.
[PMID: 17682678]
[58]
Vlahos AP, Theocharis P, Naka KK, et al. Vascular and cardiac diastolic function in children with juvenile idiopathic arthritis. Clin Exp Rheumatol 2011; 6: S30.
[59]
Satija M, Yadav TP, Sachdev N, Chhabra A, Jahan A, Dewan V. Endothelial function, arterial wall mechanics and intima media thickness in juvenile idiopathic arthritis. Clin Exp Rheumatol 2014; 32(3): 432-9.
[PMID: 24564946]
[60]
Bally M, Dendukuri N, Rich B, et al. Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data. BMJ 2017; 357: j1909.
[http://dx.doi.org/10.1136/bmj.j1909 ] [PMID: 28487435]
[61]
Gunter BR, Butler KA, Wallace RL, Smith SM, Harirforoosh S. Non-steroidal anti-inflammatory drug-induced cardiovascular adverse events: a meta-analysis. J Clin Pharm Ther 2017; 42(1): 27-38.
[http://dx.doi.org/10.1111/jcpt.12484 ] [PMID: 28019014]
[62]
Aw TJ, Haas SJ, Liew D, Krum H. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med 2005; 165(5): 490-6.
[http://dx.doi.org/10.1001/archinte.165.5.ioi50013 ] [PMID: 15710786]
[63]
Patrono C, Baigent C. Nonsteroidal anti-inflammatory drugs and the heart. Circulation 2014; 129(8): 907-16.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.113.004480 ] [PMID: 24566065]
[64]
Page J, Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem. Arch Intern Med 2000; 160(6): 777-84.
[http://dx.doi.org/10.1001/archinte.160.6.777 ] [PMID: 10737277]
[65]
Heerdink ER, Leufkens HG, Herings RMC, Ottervanger JP, Stricker BH, Bakker A. NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics. Arch Intern Med 1998; 158(10): 1108-12.
[http://dx.doi.org/10.1001/archinte.158.10.1108 ] [PMID: 9605782]
[66]
Fardet L, Fève B. Systemic glucocorticoid therapy: a review of its metabolic and cardiovascular adverse events. Drugs 2014; 74(15): 1731-45.
[http://dx.doi.org/10.1007/s40265-014-0282-9 ] [PMID: 25204470]
[67]
Shetty A, Cho W, Alazawi W, Syn WK. Methotrexate hepatotoxicity and the impact of nonalcoholic fatty liver disease. Am J Med Sci 2017; 354(2): 172-81.
[http://dx.doi.org/10.1016/j.amjms.2017.03.014 ] [PMID: 28864376]
[68]
Sakthiswary R, Chan GYL, Koh ET, Leong KP, Thong BY. Methotrexate-associated nonalcoholic fatty liver disease with transaminitis in rheumatoid arthritis. Sci world J 2014; 2014: 823763.
[http://dx.doi.org/10.1155/2014/823763 ] [PMID: 24971392]
[69]
Athyros VG, Alexandrides TK, Bilianou H, et al. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. Metabolism 2017; 71: 17-32.
[http://dx.doi.org/10.1016/j.metabol.2017.02.014 ] [PMID: 28521870]
[70]
Ismaiel A, Dumitraşcu DL. cardiovascular risk in fatty liver disease: the liver-heart axis-literature review. Front Med (Lausanne) 2019; 6: 202.
[http://dx.doi.org/10.3389/fmed.2019.00202 ] [PMID: 31616668]
[71]
Lonardo A, Sookoian S, Pirola CJ, Targher G. Non-alcoholic fatty liver disease and risk of cardiovascular disease. Metabolism 2016; 65(8): 1136-50.
[http://dx.doi.org/10.1016/j.metabol.2015.09.017 ] [PMID: 26477269]
[72]
Harris JG, Kessler EA, Verbsky JW. Update on the treatment of juvenile idiopathic arthritis. Curr Allergy Asthma Rep 2013; 13(4): 337-46.
[http://dx.doi.org/10.1007/s11882-013-0351-2 ] [PMID: 23605168]
[73]
Movva R, Brown SB, Morris DL, Figueredo VM. Anakinra for myocarditis in juvenile idiopathic arthritis. Tex Heart Inst J 2013; 40(5): 623-5.
[PMID: 24391342]
[74]
Brunner HI, Ruperto N, Zuber Z, et al. Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Ann Rheum Dis 2015; 74(6): 1110-7.
[http://dx.doi.org/10.1136/annrheumdis-2014-205351 ] [PMID: 24834925]
[75]
De Benedetti F, Brunner HI, Ruperto N, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012; 367(25): 2385-95.
[http://dx.doi.org/10.1056/NEJMoa1112802 ] [PMID: 23252525]
[76]
Giancane G, Muratore V, Marzetti V, et al. Disease activity and damage in juvenile idiopathic arthritis: methotrexate era versus biologic era. Arthritis Res Ther 2019; 21(1): 168.
[http://dx.doi.org/10.1186/s13075-019-1950-7 ] [PMID: 31287015]
[77]
Roubille C, Richer V, Starnino T, et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis 2015; 74(3): 480-9.
[http://dx.doi.org/10.1136/annrheumdis-2014-206624 ] [PMID: 25561362]
[78]
Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 2017; 377(12): 1119-31.
[http://dx.doi.org/10.1056/NEJMoa1707914 ] [PMID: 28845751]
[79]
Ridker PM, Everett BM, Pradhan A, et al. Low-dose methotrexate for the prevention of atherosclerotic events. N Engl J Med 2019; 380(8): 752-62.
[http://dx.doi.org/10.1056/NEJMoa1809798 ] [PMID: 30415610]
[80]
Shen C-C, Yao T-C, Yeh K-W, Huang JL. Association of disease activity and anti-rheumatic treatment in juvenile idiopathic arthritis with serum lipid profiles: a prospective study. Semin Arthritis Rheum 2013; 42(6): 590-6.
[http://dx.doi.org/10.1016/j.semarthrit.2012.10.002 ] [PMID: 23290689]
[81]
Yeh K-W, Lee C-M, Chang C-J, Lin YJ, Huang JL. Lipid profiles alter from pro-atherogenic into less atherogenic and proinflammatory in juvenile idiopathic arthritis patients responding to anti TNF-α treatment. PLoS One 2014; 9(6): e90757.
[http://dx.doi.org/10.1371/journal.pone.0090757 ] [PMID: 24603504]
[82]
Bašić J, Vojinović J, Jevtović-Stoimenov T, et al. Vitamin D receptor gene polymorphism influences lipid profile in patients with juvenile idiopathic arthritis. Clin Rheumatol 2019; 38(1): 117-24.
[http://dx.doi.org/10.1007/s10067-018-4264-2 ] [PMID: 30128913]
[83]
Sara DS, Luciana B, Marianna DT, et al. Etanercept improves pro-atheroscleroticbiomarkers in children with juvenile idiopaticarthritis. Pediatr Rheumatol 2011; 9: 169.
[http://dx.doi.org/10.1186/1546-0096-9-S1-P169]
[84]
Navarro-Millán I, Charles-Schoeman C, Yang S, et al. Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial. Arthritis Rheum 2013; 65(6): 1430-8.
[http://dx.doi.org/10.1002/art.37916 ] [PMID: 23460074]
[85]
Rusak M, Radzikowska U, Glowinska-Olszewska B, et al. Endothelial progenitor cell levels in juvenile idiopathic arthritis patients: effects of anti-inflammatory therapies. Pediatr Rheumatol Online J 2015; 13: 6.
[http://dx.doi.org/10.1186/s12969-015-0001-4 ] [PMID: 25705139]
[86]
Martini G, Biscaro F, Boscaro E, et al. Reduced levels of circulating progenitor cells in juvenile idiopathic arthritis are counteracted by anti TNF-α therapy. BMC Musculoskelet Disord 2015; 16: 103.
[http://dx.doi.org/10.1186/s12891-015-0555-9 ] [PMID: 25925313]
[87]
Kozera L, Andrews J, Morgan AW. Cardiovascular risk and rheumatoid arthritis--the next step: differentiating true soluble biomarkers of cardiovascular risk from surrogate measures of inflammation. Rheumatology (Oxford) 2011; 50(11): 1944-54.
[http://dx.doi.org/10.1093/rheumatology/ker232 ] [PMID: 21752870]
[88]
O’Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr. Cardiovascular Health Study Collaborative Research Group Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med 1999; 340(1): 14-22.
[http://dx.doi.org/10.1056/NEJM199901073400103 ] [PMID: 9878640]
[89]
Hodis HN, Mack WJ, LaBree L, et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med 1998; 128(4): 262-9.
[http://dx.doi.org/10.7326/0003-4819-128-4-199802150-00002 ] [PMID: 9471928]
[90]
Agca R, Heslinga SC, Rollefstad S, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis 2017; 76(1): 17-28.
[http://dx.doi.org/10.1136/annrheumdis-2016-209775 ] [PMID: 27697765]
[91]
Grobbee DE, Bots ML. Carotid artery intima-media thickness as an indicator of generalized atherosclerosis. J Intern Med 1994; 236(5): 567-73.
[http://dx.doi.org/10.1111/j.1365-2796.1994.tb00847.x ] [PMID: 7964435]
[92]
Chambless LE, Heiss G, Folsom AR, et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the atherosclerosis risk in communities (ARIC) study, 1987-1993. Am J Epidemiol 1997; 146(6): 483-94.
[http://dx.doi.org/10.1093/oxfordjournals.aje.a009302 ] [PMID: 9290509]
[93]
Robertson J, Peters MJ, McInnes IB, Sattar N. Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm. Nat Rev Rheumatol 2013; 9(9): 513-23.
[http://dx.doi.org/10.1038/nrrheum.2013.91 ] [PMID: 23774906]
[94]
Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2016; 37(29): 2315-81.
[http://dx.doi.org/10.1093/eurheartj/ehw106 ] [PMID: 27222591]
[95]
Mavrogeni SI, Kitas GD, Dimitroulas T, et al. Cardiovascular magnetic resonance in rheumatology: Current status and recommendations for use. Int J Cardiol 2016; 217: 135-48.
[http://dx.doi.org/10.1016/j.ijcard.2016.04.158 ] [PMID: 27179903]
[96]
Mavrogeni S, Fotis L, Koutsogeorgopoulou L, Vartela V, Papaevangelou V, Kolovou G. The emerging role of cardiovascular magnetic resonance imaging in the assessment of cardiac involvement in juvenile idiopathic arthritis. Rheumatol Int 2018; 38(8): 1355-62.
[http://dx.doi.org/10.1007/s00296-018-4078-1 ] [PMID: 29876652]
[97]
Gonzalez-Gay MA, Gonzalez-Juanatey C, Lopez-Diaz MJ, et al. HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. Arthritis Rheum 2007; 57(1): 125-32.
[http://dx.doi.org/10.1002/art.22482 ] [PMID: 17266100]
[98]
Rodríguez-Rodríguez L, González-Juanatey C, Palomino-Morales R, et al. TNFA -308 (rs1800629) polymorphism is associated with a higher risk of cardiovascular disease in patients with rheumatoid arthritis. Atherosclerosis 2011; 216(1): 125-30.
[http://dx.doi.org/10.1016/j.atherosclerosis.2010.10.052 ] [PMID: 21420089]
[99]
Prahalad S, Glass DN. A comprehensive review of the genetics of juvenile idiopathic arthritis. Pediatr Rheumatol Online J 2008; 6: 11.
[http://dx.doi.org/10.1186/1546-0096-6-11 ] [PMID: 18644131]
[100]
Mourão AF, Santos MJ, Mendonça S, et al. Genetic predictors of poor prognosis in portuguese patients with juvenile idiopathic arthritis: data from reuma. J Immunol Res 2015; 2015: 706515.
[http://dx.doi.org/10.1155/2015/706515 ] [PMID: 26504858]
[101]
Goldenberg J, Ferraz MB, Pessoa AP, et al. Symptomatic cardiac involvement in juvenile rheumatoid arthritis. Int J Cardiol 1992; 34(1): 57-62.
[http://dx.doi.org/10.1016/0167-5273(92)90082-E ] [PMID: 1548110]
[102]
Zeft AS, Menon SC, Miller D. Fatal myocarditis in a child with systemic onset juvenile idiopathic arthritis during treatment with an interleukin 1 receptor antagonist. Pediatr Rheumatol Online J 2012; 10: 8.
[http://dx.doi.org/10.1186/1546-0096-10-8 ] [PMID: 22490470]
[103]
Bakkaloglu A, Kirel B, Ozen S, Saatçi U. Topaloğlu, Beşbaş N. Plasma lipids and lipoproteins in juvenile chronic arthritis. Clin Rheumatol 1996; 15(4): 341-5.
[http://dx.doi.org/10.1007/BF02230355 ] [PMID: 8853166]
[104]
Argyropoulou MI, Kiortsis DN, Daskas N, et al. Distensibility and pulse wave velocity of the thoracic aorta in patients with juvenile idiopathic arthritis: an MRI study. Clin Exp Rheumatol 2003; 21(6): 794-7.
[PMID: 14740462]
[105]
Jednacz E, Rutkowska-Sak L. Assessment of the body composition and parameters of the cardiovascular risk in juvenile idiopathic arthritis. BioMed Res Int 2015; 2015: 619023.
[http://dx.doi.org/10.1155/2015/619023 ] [PMID: 25839035]
[106]
Ilisson J, Zagura M, Zilmer K, et al. Increased carotid artery intima-media thickness and myeloperoxidase level in children with newly diagnosed juvenile idiopathic arthritis. Arthritis Res Ther 2015; 17: 180.
[http://dx.doi.org/10.1186/s13075-015-0699-x ] [PMID: 26179062]
[107]
Del Giudice E, Dilillo A, Tromba L, et al. Aortic, carotid intima-media thickness and flow- mediated dilation as markers of early atherosclerosis in a cohort of pediatric patients with rheumatic diseases. Clin Rheumatol 2018; 37(6): 1675-82.
[http://dx.doi.org/10.1007/s10067-017-3705-7 ] [PMID: 29022136]
[108]
Picarelli MM, Danzmann LC, Grun LK, et al. Arterial stiffness by oscillometric device and telomere lenght in juvenile idiopathic artrhitis with no cardiovascular risk factors: a cross-sectional study. Pediatr Rheumatol Online J 2017; 15(1): 34.
[http://dx.doi.org/10.1186/s12969-017-0165-1 ] [PMID: 28472973]

Rights & Permissions Print Cite
Article Metrics
37
1
© 2024 Bentham Science Publishers | Privacy Policy